Unconfigured Ad
Collapse
Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc
| Forums | Topics | Posts | Last Post |
|---|
No forums found.
There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by laura, 05-09-2011, 04:42 AM
|
35 responses
107,625 views
0 reactions
|
Last Post
by laura
12-05-2013, 02:37 AM
|
||
|
Started by sci_guy, 01-23-2008, 11:19 PM
|
236 responses
684,182 views
1 reaction
|
Last Post
by ECO
12-25-2009, 06:45 PM
|
||
|
Started by kentk, 03-01-2012, 02:37 AM
|
0 responses
2,389 views
0 reactions
|
Last Post
by kentk
03-01-2012, 02:37 AM
|
||
|
Started by Noa, 03-01-2012, 02:21 AM
|
0 responses
1,737 views
0 reactions
|
Last Post
by Noa
03-01-2012, 02:21 AM
|
||
|
Started by ifiddes, 02-28-2012, 11:40 AM
|
5 responses
3,093 views
0 reactions
|
Last Post
by swaraj
03-01-2012, 12:57 AM
|
||
|
Started by yangxz, 03-01-2012, 12:11 AM
|
0 responses
1,965 views
0 reactions
|
Last Post
by yangxz
03-01-2012, 12:11 AM
|
||
|
Started by moriah, 02-29-2012, 08:14 AM
|
4 responses
2,316 views
0 reactions
|
Last Post
by moriah
03-01-2012, 12:10 AM
|
||
|
Started by shuang, 02-24-2012, 02:20 PM
|
2 responses
2,467 views
0 reactions
|
Last Post
by flxlex
03-01-2012, 12:08 AM
|
||
|
Started by pifpaf, 03-01-2012, 12:04 AM
|
0 responses
1,572 views
0 reactions
|
Last Post
by pifpaf
03-01-2012, 12:04 AM
|
||
|
Started by niteesh.prasad, 02-29-2012, 10:59 PM
|
0 responses
2,168 views
0 reactions
|
Last Post
|
||
|
Started by Kennels, 07-03-2011, 09:54 PM
|
1 response
3,496 views
0 reactions
|
Last Post
by ron128
02-29-2012, 10:03 PM
|
||
|
Started by bluelotus, 02-26-2012, 10:23 PM
|
5 responses
2,066 views
0 reactions
|
Last Post
by bluelotus
02-29-2012, 07:20 PM
|
No topics found.
-
Page of 0
-
Filter
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.
Recent Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Yesterday, 12:17 PM
|
0 responses
13 views
0 reactions
|
Last Post
by SEQadmin2
Yesterday, 12:17 PM
|
||
|
Started by SEQadmin2, 07-23-2026, 11:41 AM
|
0 responses
14 views
0 reactions
|
Last Post
by SEQadmin2
07-23-2026, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|